SCHNEIDER, Benjamin; BOYER, Arnaud; CICCOLINI, Joseph; BARLESI, Fabrice; WANG, Kenneth; BENZEKRY, Sébastien; MOCHEL, Jonathan

doi:10.1002/psp4.12415

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

SCHNEIDER, Benjamin
Iowa State University [ISU]

BOYER, Arnaud
Simulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]

CICCOLINI, Joseph
Simulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]

Idioma

Article de revue

Este ítem está publicado en

CPT: Pharmacometrics and Systems Pharmacology. 2019-04-19

American Society for Clinical Pharmacology and Therapeutics ; International Society of Pharmacometrics

Resumen en inglés

Bevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) is a first line therapeutic for advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BE V- PEM/CIS has a narrow therapeutic window. Therefore, it is an attractive target for administration schedule optimization. The present study leverages our previous work on BEV-PEM/CIS pharmacodynamic modeling in NSCLC-bearing mice to estimate the optimal gap in the scheduling of sequential BEV-PEM/CIS. We predicted the optimal gap in BEV-PEM/CIS dosing to be 2.0 days in mice and 1.2 days in humans. Our simulationssuggest that the efficacy loss in scheduling BEV-PEM/CIS at too great of a gap is much less than the efficacy loss in scheduling BEV-PEM/CIS at too short of a gap.< Leer menos

Palabras clave en inglés

Cancers

Optimization

Oncology

Pharmacokinetics-pharmacodynamics

Mathematical modeling

Metadatos

Compartir este ítem

Licencia de uso del documento

Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Orígen

Centros de investigación